https://www.hep-druginteractions.org/checker

No Interaction Expected

Glecaprevir/Pibrentasvir

Dextromethorphan

Summary:

Coadministration of dextromethorphan (30 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) decreased dextromethorphan Cmax and AUC by 30% and 25% (n=12). This was not clinically significant and no dose adjustment is required.

Description:

Drug-drug interaction studies were performed with dextromethorphan and showed no clinically significant interactions with Maviret.
Maviret Summary of Product Characteristics, AbbVie Ltd, July 2017.

No dose adjustment is required when Mavyret is coadministered with dextromethorphan. Coadministration of dextromethorphan (30 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) decreased dextromethorphan Cmax and AUC by 30% and 25% (n=12).
Mavyret Prescribing Information, AbbVie Inc, August 2017.